文献速递妇科

多次复发性卵巢上皮性癌行三次及以上肿瘤细胞减灭术的预后及相关因素分析

[Analysis of prognosis and associated factors in multiple recurrent epithelial ovarian cancer with three times or more cytoreductive surgeries].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2023-01-01

回顾性分析复旦大学附属妇产科医院2015年1月1日至2022年1月30日收治的23例多次复发卵巢癌行3次及以上肿瘤细胞减灭术患者的临床资料,3次及以上手术R0率88%(28/32),术后并发症发生率47%(15/32),Ⅲ级及以上仅3%(1/32),TCS后3年生存率57.6%,单因素分析显示年龄、手术间隔、无转移性腹膜癌、无腹水、铂敏感等与生存相关。

要点

  • 多次复发卵巢癌行3次及以上肿瘤细胞减灭术R0率88%(28/32),Ⅲ级及以上并发症仅3%(1/32)。
  • TCS后中位随访31.1个月,20例(87%,20/23)复发,8例(35%,8/23)死于卵巢癌。
  • 单因素分析示年龄、SCS与TCS间隔>16个月、无转移性腹膜癌与无进展生存相关(P均<0.05)。

核心结论

  • 对有望达到R0且并发症可控的多次复发卵巢癌患者行3次及以上肿瘤细胞减灭术是可行的。
  • 对大量腹水、前次肿瘤细胞减灭术未达R0的患者需谨慎评估手术利弊。
  • TFI较长、与前次手术间隔时间较长患者的生存获益可能更大。

研究设计与样本

  • 回顾性分析2015年1月1日至2022年1月30日复旦大学附属妇产科医院收治的23例多次复发(≥2次)行3次及以上肿瘤细胞减灭术的卵巢上皮性癌患者临床病理及随访资料。
  • 采用单因素Cox比例风险模型分析影响预后的相关因素。

主要发现

  • 23例患者中位年龄48岁(44~55岁),行TCS者18例、四次2例、五次2例、六次1例。
  • 3次及以上肿瘤细胞减灭术共32例次,R0率88%(28/32),术后并发症发生率47%(15/32),Ⅲ级及以上仅3%(1/32)。
  • 多次复发时最大肿瘤最大径10.0 cm,多发性复发转移20例次(62%,20/32)。
  • TCS后中位随访31.1个月(20.6~43.9个月),20例(87%,20/23)复发,8例(35%,8/23)死于卵巢癌;TCS达R0者22例术后3年总生存率57.6%,1例残留灶≥1 cm者于TCS后9.2个月死亡。
  • 单因素分析:年龄、PDS与SCS间隔>32个月、SCS与TCS间隔>16个月、无转移性腹膜癌与TCS后无进展生存相关(P均<0.05);SCS后TFI>10个月、SCS与TCS间隔>16个月、无腹水、铂敏感与TCS后疾病特异性生存相关(P均<0.05)。

临床怎么用

  • 对有望达到R0且并发症可控的多次复发卵巢癌患者,作者认为行3次及以上肿瘤细胞减灭术是可行的。
  • 对大量腹水、前次肿瘤细胞减灭术未达R0的患者,作者认为需谨慎评估手术利弊。
  • 作者认为TFI较长、与前次手术间隔时间较长的患者行3次及以上肿瘤细胞减灭术的生存获益可能更大。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the prognosis of epithelial ovarian cancer patients with multiple recurrences (≥2 times) who underwent three times or more cytoreductive surgeries, and to analyze the factors associated with prognosis. Methods: The clinicopathological data and follow-up data of 23 patients with ovarian cancer admitted to the Obstetrics and Gynecology Hospital of Fudan University from January 1, 2015 to January 30, 2022 with three times or more cytoreductive surgeries were collected. The degree of surgical resection, site of recurrence and metastasis, postoperative complications, and prognosis were retrospectively analyzed. The univariate Cox proportional hazards model was performed to identify the variables associated with survival. Results: (1) The median age of 23 patients with multiple recurrent ovarian cancer was 48 years old (44-55 years). Among them, 18 cases underwent tertiary cytoreductive surgery (TCS), 2 cases underwent quaternary cytoreductive surgery, 2 cases underwent quinary cytoreductive surgery, and 1 case underwent senary cytoreductive surgery. Among the 23 patients with multiple recurrent ovarian cancer, 21 cases (91%, 21/23) had serous carcinoma, 16 cases (70%, 16/23) had advanced stage (stage Ⅲ-Ⅳ), and 19 cases (83%, 19/23) had high differentiation. (2) Based on the premise that satisfactory cytoreduction was achieved by primary debulking surgery (PDS) and no visible residual disease (R0) was achieved by secondary cytoreductive surgery (SCS), the maximum diameter of the recurrent tumors was up to 10.0 cm and 62% (20/32) of patients with multiple metastatic sites. The R0 rate for three times or more cytoreductive surgeries (32 times in total) reached 88% (28/32), with a postoperative complication rate of 47% (15/32), and only 3% (1/32) for grade Ⅲ or above. During a median follow-up time of 31.1 months (20.6-43.9 months) after TCS, 20 patients (87%, 20/23) recurred after TCS, and 8 patients (35%, 8/23) eventually died of ovarian cancer. Among them, the three-year postoperative survival rate of 22 patients with R0 was 57.6%, and the patient with residual lesions ≥1 cm died at 9.2 months after TCS. (3) In univariate analysis, ages, the time interval between PDS and SCS >32 months, the interval between SCS and TCS >16 months, and no metastatic peritoneal carcinoma were associated with longer progression free survival after TCS (all P<0.05); while treatment-free interval (TFI) >10 months after SCS, the interval between SCS and TCS >16 months, no ascites and platinum-sensitive status were associated with disease-specific survival after TCS (all P<0.05). Conclusions: It is feasible to perform three times or more cytoreductive surgeries in patients with multiple recurrent ovarian cancer who are expected to achieve R0 and have manageable complications. However, the pros and cons of surgery need to be carefully evaluated for the patients whose ascites are massive and whose previous cytoreduction does not achieve R0. A prolonged TFI and previously longer surgical interval might get potential survival benefits. 目的: 探讨多次(≥2次)复发行3次及以上肿瘤细胞减灭术的卵巢上皮性癌(卵巢癌)患者的预后,并分析预后影响因素。 方法: 收集2015年1月1日至2022年1月30日复旦大学附属妇产科医院收治的多次复发行3次及以上肿瘤细胞减灭术的23例卵巢癌患者的临床病理资料及随访资料,回顾性分析其手术切除程度、复发转移部位、术后并发症及预后,并采用单因素Cox比例风险模型对影响患者预后的相关因素进行分析。 结果: (1)23例多次复发的卵巢癌患者的中位年龄为48岁(44~55)岁;其中,行三次肿瘤细胞减灭术(TCS)者18例,行四次肿瘤细胞减灭术者2例,行五次肿瘤细胞减灭术者2例,行六次肿瘤细胞减灭术者1例。23例多次复发的卵巢癌患者中,以浆液性癌[21例(91%,21/23)]、晚期[Ⅲ~Ⅳ期;16例(70%,16/23)]、高分化[19例(83%,19/23)]为主。(2)基于初次肿瘤细胞减灭术(PDS)达到满意减瘤(残留灶最大径<1 cm)、二次肿瘤细胞减灭术(SCS)达到无肉眼可见残留灶(R0)的前提下,行3次及以上肿瘤细胞减灭术共32例次,多次复发时最大肿瘤的最大径为10.0 cm,以多发性复发转移为主[20例次(62%,20/32)];3次及以上肿瘤细胞减灭术的R0率为88%(28/32);术后并发症发生率为47%(15/32),其中Ⅲ级及以上并发症仅占3%(1/32)。TCS后的中位随访时间为31.1个月(20.6~43.9个月);23例行TCS的患者中,20例(87%,20/23)TCS后复发,其中8例(35%,8/23)最终因卵巢癌死亡;TCS达到R0的患者22例,其术后3年总生存率为57.6%,而1例残留灶≥1 cm的患者于TCS后9.2个月死亡。(3)单因素分析显示,年龄、PDS与SCS间隔时间、SCS与TCS间隔时间、TCS时有无转移性腹膜癌与TCS后的无进展生存时间均显著相关(P均<0.05);SCS后无治疗间隔时间(TFI)、SCS与TCS间隔时间、TCS时有无腹水、铂敏感性与TCS后的疾病特异性生存时间均显著相关(P均<0.05)。 结论: 对有望达到R0且并发症可控的多次复发卵巢癌患者进行3次及以上肿瘤细胞减灭术是可行的,但对于大量腹水、前次肿瘤细胞减灭术未达到R0的患者需谨慎评估手术利弊;3次及以上肿瘤细胞减灭术对于TFI较长、与前次手术的间隔时间较长患者的生存获益可能更大。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zou RY, Yuan L, Chen M, et al. [Analysis of prognosis and associated factors in multiple recurrent epithelial ovarian cancer with three times or more cytoreductive surgeries]. Zhonghua Fu Chan Ke Za Zhi. 2023. PMID: 36935197. doi:10.3760/cma.j.cn112141-20221225-00773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。